"Pharma Giants Novo Nordisk and Eli Lilly Address Weight Loss Drug Supply Challenges"
TL;DR Summary
Novo Nordisk and Eli Lilly are still struggling to meet the high demand for their weight loss and diabetes drugs due to supply shortages. Eli Lilly has doubled its capacity for producing injectable incretin drugs and plans to increase production further in 2024, while Novo Nordisk's parent company, Novo Holdings, will acquire drug manufacturer Catalent to improve supply. In other news, Elon Musk's Neuralink has implanted its brain-computer interface into a human patient for the first time, marking a significant milestone in the development of technology to help patients with paralysis control external technologies using only their mind.
Topics:business#eli-lilly#health-pharmaceuticals#neuralink#novo-nordisk#supply-issues#weight-loss-drugs
- Healthy Returns: Novo Nordisk, Eli Lilly are tackling weight loss drug supply woes CNBC
- Novo Nordisk buys manufacturing power as it seeks to ramp up Wegovy The Washington Post
- Eli Lilly Is Worried That the Novo-Catalent Deal Could Dent Its Ability to Make Drugs The Wall Street Journal
- Why Novo Nordisk Stock Crushed the Market on Monday Yahoo Finance
- Wegovy maker Novo inks $16.5 billion acquisition of Catalent to boost supply Axios
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
4 min
vs 5 min read
Condensed
89%
923 → 98 words
Want the full story? Read the original article
Read on CNBC